Drug Database
Back to search

United Kingdom· GB-APID-30759111000001108

Zykadia 150mg capsules

A ceritinib product containing ceritinib, registered in United Kingdom by Novartis Pharmaceuticals UK Ltd. The same ATC class is registered in 13 of our 19 countries.

ATC L01ED02

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedZykadia 150mg capsulesATCL01ED02REGISTER NO.GB-APID-3075911100000…PACKS LISTED1CHECKEDSeptember 13, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ceritinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ceritinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01ED02 (ceritinib), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 8 of them publish a price we can compare per daily dose
Search ceritinib products by name

Ceritinib · ATC L01ED02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ceritinib costs, country by country.

Normalised to the WHO defined daily dose (0.45 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ceritinib · price per daily dose (0.45 g)

USD · FX 28 Sept 2026

  • CH Switzerland$188.22
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Ceritinib
Manufacturer
Novartis Pharmaceuticals UK Ltd
Country
United Kingdom (GB)
ATC code
L01ED02
ATC class
Ceritinib
Defined daily dose
0.45 g, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 1

  • gtin
    5010678926071

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

769 interactions on record for ceritinib.

Graded by severity as the source publishes them — 449 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ceritinib against other medicinesHow interaction checks work

Ceritinib · interactions on record

769 records

  • 449 severe
  • 307 moderate
  • 13 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ceritinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ceritinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Zykadia
  • Liechtenstein · Zykadia
  • Norway · Zykadia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ad7a5aa8-0ea3-415c-802f-0a99f79693b1
GET /v1/drugs/ad7a5aa8-0ea3-415c-802f-0a99f79693b1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "30759111000001108",
  "desc": "Zykadia 150mg capsules (Novartis Pharmaceuticals UK Ltd)",
  "form": "Oral capsule",
  "vpid": "30758811000001108",
  "source": "dmd",
  "vtm_id": "775130007",
  "strength": "150 mg",
  "substance": "Ceritinib",
  "ingredient": "Ceritinib",
  "supplier_code": "2920101000001102"
}
API referenceMCP serverPlans

See everything about ceritinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console